Skip to content

Silence Therapeutics

US · SLN #3615 by market cap
9.82 -0.01 -0.10%
Live - 5344 symbols - heartbeat 286s ago · 2026-10-08 07:29
Pre-market 10.02 +2.04%
After-hours 9.82 0.00%
Market cap
610.35M
P/B
15.86
EPS
-1.89
Reader sentiment Are you bullish or bearish on SLN?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    BMO Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Cuts Target Price to $15
    Market Newswire · 2025/6/14
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Medline, Inc. Class A (MDLN) and Silence Therapeutics (SLN)
    TipRanks · 2026/2/26
  • Rating change
    Goldman Sachs Initiates Silence Therapeutics(SLN.US) With Sell Rating, Announces Target Price $4
    Market Newswire · 2025/3/4
  • Silence Therapeutics Expects Offering to Close on or About Aug. 13 SLN
    Dow Jones · 2026/8/12
  • Rating change
    Cantor Fitzgerald Initiates Silence Therapeutics(SLN.US) With Buy Rating
    Market Newswire · 2026/6/24
  • H.C. Wainwright Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $75
    Market Newswire · 2026/9/22
  • Rating change
    Silence Therapeutics (SLN) Receives a Buy From H.C. Wainwright
    TipRanks · 2026/5/27
  • Rating change
    Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/6/12
  • Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $32
    Market Newswire · 2026/8/11
  • Rating change
    Chardan Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating
    Market Newswire · 2026/8/17
  • Rating change
    H.C. Wainwright Reaffirms Their Buy Rating on Silence Therapeutics (SLN)
    TipRanks · 2026/4/7
  • Rating change
    William Blair Maintains Silence Therapeutics(SLN.US) With Buy Rating, Announces Target Price $5.5
    Market Newswire · 2026/3/6
  • William Blair Maintains Silence Therapeutics(SLN.US) With Buy Rating
    Market Newswire · 2026/9/11
  • Rating change
    Jefferies Maintains Silence Therapeutics(SLN.US) With Buy Rating, Cuts Target Price to $30
    Market Newswire · 2025/2/28
  • Rating change
    Goldman Sachs Maintains Silence Therapeutics(SLN.US) With Sell Rating, Maintains Target Price $4
    Market Newswire · 2026/3/6
  • Rating change
    Chardan Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Cuts Target Price to $27
    Market Newswire · 2026/5/8
  • Rating change
    Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Cuts Target Price to $25
    Market Newswire · 2025/5/10
  • A Quick Look at Today's Ratings for Silence Therapeutics(SLN.US), With a Forecast Between $27 to $75
    Market Newswire · 2026/8/11
  • Rating change
    William Blair Initiates Silence Therapeutics(SLN.US) With Buy Rating
    Market Newswire · 2025/2/28
  • Rating change
    BMO Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Cuts Target Price to $25
    Market Newswire · 2025/3/5

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 07:29:00 · For reference only, not investment advice and not tailored to your situation.